| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MARVELD3 |
| Uniprot No | Q96A59 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-401aa |
| 活性数据 | MEDPSGAREPRARPRERDPGRRPHPDQGRTHDRPRDRPGDPRRKRSSDGNRRRDGDRDPKRDQERDGNRDRNRDRERERERERDPDRGPRRDTHRDAGPRAGEHGVWEKPRQSRTRDGARGLTWDAAAPPGPAPWEAPEPPQPQRKGDPGRRRPESEPPSERYLPSTPRPGREEVEYYQSEAEGLLECHKCKYLCTGRACCQMLEVLLNLLILACSSVSYSSTGGYTGITSLGGIYYYQFGGAYSGFDGADGEKAQQLDVQFYQLKLPMVTVAMACSGALTALCCLFVAMGVLRVPWHCPLLLVTEGLLDMLIAGGYIPALYFYFHYLSAAYGSPVCKERQALYQSKGYSGFGCSFHGADIGAGIFAALGIVVFALGAVLAIKGYRKVRKLKEKPAEMFEF |
| 分子量 | 71.3 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人MARVELD3蛋白的参考文献及相关摘要内容：
1. **文献名称**：*MARVELD3 regulates tight junction formation and motility in epithelial cells*
**作者**：Steed, E., et al.
**摘要**：该研究阐明了MARVELD3作为紧密连接蛋白的功能，利用重组人MARVELD3蛋白进行体外实验，发现其通过调控细胞黏附和细胞骨架重塑影响上皮细胞迁移，为癌症转移机制提供了新视角。
2. **文献名称**：*Downregulation of MARVELD3 in tumors promotes EMT and metastasis*
**作者**：Latorre, I.J., et al.
**摘要**：研究显示，MARVELD3在多种癌症组织中表达下调，并利用重组蛋白实验证明其抑制上皮间质转化（EMT）的功能，为开发靶向治疗策略提供依据。
3. **文献名称**：*MARVELD3 interaction with hepatitis C virus nonstructural proteins modulates viral replication*
**作者**：Sainz, B., et al.
**摘要**：通过重组MARVELD3蛋白研究发现，其与HCV非结构蛋白相互作用可能影响病毒复制复合体的组装，提示其在抗病毒治疗中的潜在价值。
4. **文献名称**：*Structural characterization of MARVELD3 and its role in endothelial barrier regulation*
**作者**：Zheng, Y., et al.
**摘要**：通过重组蛋白表达和结构分析，揭示了MARVELD3的跨膜结构域对维持内皮屏障完整性的作用，并发现其磷酸化修饰参与炎症相关屏障破坏。
注：以上文献信息基于领域内研究趋势模拟，具体内容需参考实际发表的论文。建议通过PubMed或Web of Science检索最新文献。
Marveld3 is a member of the MARVEL (MAL and related proteins for vesicle trafficking and membrane link) domain-containing protein family, which is implicated in membrane dynamics and intercellular junction regulation. Discovered as a paralog of occludin, Marveld3 shares structural features such as four transmembrane domains and a conserved MARVEL domain crucial for membrane apposition and protein-protein interactions. It is predominantly expressed in epithelial and endothelial cells, localizing to tight junctions where it contributes to barrier integrity, though its role appears more regulatory than structural compared to occludin.
Research highlights Marveld3's involvement in cell proliferation, differentiation, and inflammatory responses. It modulates extracellular signal-regulated kinase (ERK) and phosphoinositide 3-kinase (PI3K) pathways, influencing tissue homeostasis and disease progression. Dysregulation of Marveld3 has been linked to pathological conditions including cancers (e.g., colorectal, hepatocellular carcinoma) and chronic inflammatory diseases, where altered expression correlates with metastasis and epithelial-mesenchymal transition (EMT).
Recombinant human Marveld3 protein, produced via heterologous expression systems like E. coli or mammalian cells, retains post-translational modifications critical for functional studies. It serves as a key tool for investigating tight junction dynamics, cellular signaling crosstalk, and therapeutic target validation. Current studies focus on clarifying its tissue-specific roles, regulatory mechanisms, and potential in restoring barrier function during inflammation or carcinogenesis, positioning it as a promising biomarker and intervention target in epithelial-related pathologies.
×
